Acadia’s Trofinetide Shows Efficacy In Rett Syndrome, But Safety Looks Shaky

Trofinetide could be the first approved drug for Rett patients after hitting both co-primary endpoints in a Phase III trial, but high rates of diarrhea and vomiting raise questions.

Diagnosis Rett syndrome, pills and stethoscope.
Acadia's Phase III data could position trofinetide for first drug approval in Rett syndrome

More from Clinical Trials

More from R&D